Results from real-world evidence (RWE) studies to be presented at OPTIONS XII show the effectiveness of cell-based and MF59® adjuvanted influenza vaccines. Results from different studies suggested improved relative vaccine effectiveness (rVE) of cell-based vaccines compared with egg-based vaccines in preventing test-confirmed influenza across different age groups, including children as young as six months.1,2 Results from a real-world study covering the 2023/24 season showed that cell-based vaccine was effe ...

Core Points - CSL Seqirus, in partnership with BARDA, will expand its MF59® adjuvant reserves to support U.S. pandemic preparedness efforts, increasing the inventory to the equivalent of 40 million doses through a $121.4 million multi-year award [1][2][3] Company Overview - CSL Seqirus is a major player in the global influenza vaccine market and is part of CSL (ASX: CSL), which has a diverse portfolio including treatments for hemophilia and immune deficiencies [7][9] - The company operates state-of-the-art production facilities in the U.S., U.K., and Australia, utilizing advanced technologies to produce a wide range of influenza vaccines [7][9] Industry Context - The MF59® adjuvant is crucial for pandemic preparedness as it enhances immune response while reducing the amount of antigen needed, thereby increasing the number of available vaccine doses [3][5] - The current public health risk from avian influenza A(H5) is low, but the CDC is monitoring the situation closely due to recent outbreaks in poultry and dairy cows [4][6] - Historical data indicates that pandemics can occur unpredictably, with the 1918 influenza pandemic being the most severe, resulting in an estimated 50 million deaths worldwide [5]

Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients 1-5 Zeria Pharmaceutical Co., Ltd. to market Veltassa® in Japan ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd. (Zeria), marketing authorization approval for Veltassa® for the treatment of adult patients with hyperkalemia, a condi ...

PHILADELPHIA, Sept. 17, 2024 (GLOBE NEWSWIRE) -- In an era where artificial intelligence (AI) is transforming industries and reshaping our daily lives, it is more important than ever to equip the next generation with the skills and knowledge to harness these powerful tools. The Mark Cuban Foundation, in partnership with CSL, is proud to bring the only artificial intelligence (AI) camp of its kind, free of charge, to high school students in Philadelphia. Applications for the no-cost bootcamp are closing Sept ...

Industry Collaboration and Membership - Accumulus Synergy welcomes CSL as its first member organization, marking significant progress in advancing critical therapies globally [1] - The membership model aims to shape regulatory policy, raise awareness of global harmonization, and drive digital transformation to accelerate therapies worldwide [2] - Membership is open to life sciences organizations, health associations, private/non-profit foundations, and other institutions, offering access to resources, thought leadership, and networking opportunities [4] Strategic Vision and Impact - Accumulus Synergy is described as a catalyst for change, pioneering an industry paradigm shift for regulatory harmonization and digital transformation [3] - The collaboration between Accumulus and CSL is expected to amplify their collective impact and drive positive change on a global scale [2] - The focus is on advancing opportunities for regulatory data convergence, data harmonization, and digital transformation [5] Company Overviews - Accumulus Synergy is a global nonprofit industry association developing a transformative data exchange platform to enhance collaboration between life sciences organizations and global Regulatory Authorities [6] - CSL is a global biotechnology company with a portfolio of lifesaving medicines, vaccines, and therapies, operating in over 100 countries with 32,000 employees [7] Media Contact - Media inquiries can be directed to Allison Mari at Accumulus Synergy [8]

josefkubes/iStock Editorial via Getty Images CSL Limited (OTCQX:CSLLY) (OTCQX:CMXHF) [CSL:AU] stock is still assigned a Hold investment rating. CSLLY is expected to register a decent low-teens percentage bottom line growth for fiscal year 2025 (YE June 30, 2025), taking into account the positive prospects for the Behring segment. But the company's Seqirus and Vifor segments are likely to underperform going forward, and this has resulted in a FY 2025 earnings guidance miss. The mixed outlook for CSL Limited' ...

CSL Limited (OTCQX:CSLLY) Q4 2024 Results Conference Call August 12, 2024 9:00 PM ET Company Participants Joy Linton - CFO Chris Cooper - Head, IR Paul McKenzie - MD, CEO & Executive Director Ken Lim - Chief Strategy Officer Conference Call Participants Lyanne Harrison - Bank of America Saul Hadassin - Barrenjoey Gretel Janu - Evans & Partners Steve Wheen - Jarden Andrew Goodsall - MST Marquee David Low - JPMorgan Craig Wong-Pan - RBC David Stanton - Jefferies Laura Sutcliffe - UBS Mathieu Chevrier - Citi D ...

CSL Seqirus is the only manufacturer to offer a differentiated influenza vaccine for all eligible people aged six months and older in the United States. Centers for Disease Control and Prevention (CDC) trend findings indicate a significant decline in influenza vaccination rates, which poses a serious risk to public health infrastructure and underscores the importance of receiving an annual influenza vaccination.1,2 According to the CDC, it is recommended that all eligible people aged six months and older re ...

CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government's outbreak and preparedness response. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and livestock have been reported in the U.S. Fourth avian influenza pandemic preparedness award to CSL Seqirus under a multi-year agreement with Biomedical Advanced Research and Development Authority (BARDA). SUMMIT, N.J., May 30, 2024 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), ...

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster. KING OF PRUSSIA, Pa. and SAN DIEGO, May 20, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY ...